|
gptkbp:instanceOf
|
gptkb:chemical_compound
bronchodilator
muscarinic antagonist
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
R03BB05
|
|
gptkbp:brand
|
gptkb:Eklira
gptkb:Tudorza
|
|
gptkbp:CASNumber
|
320345-99-1
|
|
gptkbp:chemicalClass
|
quaternary ammonium compound
|
|
gptkbp:contraindication
|
hypersensitivity to aclidinium
|
|
gptkbp:developedBy
|
gptkb:Almirall
|
|
gptkbp:eliminationHalfLife
|
5 to 8 hours
|
|
gptkbp:form
|
inhalation powder
|
|
gptkbp:hasMolecularFormula
|
C26H30BrNO4S
|
|
gptkbp:hasSMILES
|
CCOC(=O)C1=CC=CC=C1C2=CC=CC=C2C(=O)OCC[N+](C)(C)C.[Br-]
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
aclidinium bromide
|
|
gptkbp:KEGGID
|
D09741
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
muscarinic receptor antagonist
|
|
gptkbp:molecularWeight
|
485.49 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2103836
DB08896
11520529
|
|
gptkbp:routeOfAdministration
|
inhalation
|
|
gptkbp:sideEffect
|
headache
cough
dry mouth
nasopharyngitis
|
|
gptkbp:therapeuticArea
|
respiratory system
|
|
gptkbp:UNII
|
K9U0A0D42J
|
|
gptkbp:usedFor
|
chronic obstructive pulmonary disease
|
|
gptkbp:bfsParent
|
gptkb:Duaklir_Pressair
gptkb:Tudorza
|
|
gptkbp:bfsLayer
|
7
|